ArticleCytotechnology2025
CXCL1 promotes diabetic foot ulcer through activation of the TNF-α signaling pathway.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcer (DFU) is an immune disease associated with diabetes. C-X-C ligand 1 (CXCL1) is a pro-inflammatory factor. Both of them have been reported to associated with the activation of oxidative stress and inflammation. This study aimed to explore the relationship between CXCL1 action mechanism and DFU occurrence through studying inflammation and oxidative stress. Firstly, used bioinformatics analysis to investigate highly expressed genes/pathways in DFU based on GEO database. After that, CXCL1-specific shRNA (sh-CXCL1) was transfected in to human umbilical vein epithelial cells (HUVEC) in high glucose (HG) condition to establish sh-CXCL1 cells, then CXCL1 expression, cell viability, inflammatory levels and oxidative stress were verified. Moreover, TNF-α overexpression plasmids (oe-TNF-α) were transfected to the HG + sh-CXCL1 group cells, and TNF-α expression, cell viability, inflammatory levels and oxidative stress were also assessed. Bioinformatics analysis indicated that CXCL1 and TNF-α were highly expressed in DFU, and there was a positive correlation between them. After transfection with sh-CXCL1, in HG conditions, the expression levels of CXCL1 and TNF-α in human umbilical vein endothelial cells (HUVEC) were significantly decreased, and oxidative stress and inflammatory responses were inhibited, while cell viability was significantly increased. However, after transfection of oe-TNF-α in sh-CXCL1 cells, all these effects were reversed. CXCL1 activates the TNF-α signaling pathway, increase oxidative stress and inflammatory response, thereby inducing DFU occurrence. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-025-00821-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.